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ABSTRACT 
Objective: Cardiotrophin-1 (CT-1) shares some similarities with other cytokines, and 
participates in the control of energy metabolism. Higher circulating levels are observed 
in obese humans, but little information is gathered in weight loss (WL) programs. 
Therefore, we aimed to investigate the association of serum CT-1 levels with metabolic 
variables and the risk of developing metabolic syndrome (MetS) after a WL program in 
overweight/obese children. 
Subjects and Methods: Forty-four overweight/obese children (mean age 11.5 yr; 50% 
males) undergoing a 10-week WL program were enrolled. Subjects were dichotomized 
at the median of Body Mass Index-Standard Deviation Score (BMI-SDS) change, as 
high and low responders after intervention. 
Results: CT-1 levels were significantly reduced (-48 fmol/mL, p=0.043) in the high 
responder group after the WL program. They had significantly lower body weight (-3.7 
kg, p<0.001), body fat mass (-8%, p<0.001), BMI-SDS (-0.78, p<0.001) and waist 
circumference (-5.4 cm, p<0.001), and a significant improvement in lipid and glucose 
profiles (p<0.05). Interestingly, decreased CT-1 levels significantly predicted changes 
in total cholesterol (41%) and LDL-cholesterol (28%). Moreover, in our participants the 
lower the CT-1 levels, the higher the reduction in MetS risk components, after the 10-
week intervention, (p-ANCOVA=0.040, p-trend=0.024).  
Conclusion: We showed, for the first time, a reduction in serum CT-1 levels after a WL 
program and this decrease in CT-1 was strongly associated with a reduction in 
cholesterol levels and in MetS risk factors in overweight/obese children. Our findings 
may suggest that CT-1 could be an indirect marker for the diagnosis of MetS in this 
population.  
KEY WORDS: Child; Intervention studies; Obesity; Cytokine. 
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1. INTRODUCTION 
The prevalence of childhood obesity has almost tripled in US children and adolescents 
since 1980 [1] and in some countries there is an age-specific stabilization in these 
elevated values [2,3]. In Spain, a national survey in 2007 showed that 10.3% of the 
population aged 2-15 yr was obese and 18.8% was overweight [4]. The factors 
associated with overweight and obesity are complex, such as eating habits, daily 
physical activity and social, environmental and biological determinants. In fact, 
nutritional interventions are a valuable strategy to face this serious problem [3,5]. 
A successful weight loss (WL) program in overweight and obese children and 
adolescents is usually accompanied by a general metabolic improvement and a 
reduction in several cardiovascular risk factors [6-9]. Specifically, in intervention 
studies with 9-13 yr obese children, increased circulating adiponectin levels and lower 
HOMA-IR [8,10-12] were described, together with a reduction in fat mass, Body Mass 
Index (BMI) or Body Mass Index-Standard Deviation Score (BMI-SDS). Previous 
studies have shown that an improvement in body composition and cardiometabolic risk 
can be seen with a BMI-SDS reduction of ≥0.25 in obese adolescents, while greater 
benefits accrue from losing at least 0.5 BMI-SDS [6].  
Concerning changes in blood lipids, a recent systematic review with meta-analysis on 
the effectiveness of lifestyle interventions in obese children, showed that lifestyle 
intervention did significantly lower total cholesterol compared with no treatment (-0.40 
mmol/L) in 440 obese children aged 8-16 yr [5]. A similar effect was found for 
triglycerides, the pooled mean difference being -0.20 mmol/L [5]. 
In recent years, cardiotrophin-1 (CT-1) has emerged as a new player in the control of 
energy metabolism potentially linked to obesity and type 2 diabetes [13]. CT-1 is a 201 
amino acid protein member of the interleukin-6 (IL-6) superfamily of cytokines. It 
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mediates a pleiotropic set of survival effects through a receptor system; consisting of 
glycoprotein 90 or leukemia inhibitory factor receptor beta (LIFRb) and a common 
signal transducer, the glycoprotein 130 (gp130) [14]. CT-1 is expressed in a variety of 
organs from human heart to liver, being nutritionally regulated [13]. It plays a role in 
the control of energy metabolism sharing some similarities with leptin and other 
cytokines such as IL-6 or CNTF (ciliary neurotrophic factor) [13,15]. Interestingly, in 
animals CT-1 activates fat utilization, displays glucose-lowering activity and also shows 
anorexigenic properties [13]. Thus, experimental data are promising for the therapeutic 
implication of CT-1 in obesity [16].  
Endogenous CT-1 has prolonged stability in whole blood, hence permitting its 
development in the routine clinical investigation of patients [17]. It seems that 
circulating CT-1 could be considered as a promising biomarker in patients with 
cardiovascular diseases and the metabolic syndrome (MetS). However, few studies have 
been performed in obese human subjects. Two studies showed that obese adults had 
higher circulating CT-1 levels than normal-weight subjects [18,19] and in overweight 
adolescents no differences in plasma CT-1 were found when compared to control 
subjects [20]. There is also no information about the effect of a WL program in CT-1 
levels. Thus, our aim was to evaluate changes in serum CT-1 levels after a WL program 
in overweight/obese children and to investigate the relationship with the risk of 
developing the MetS and other metabolic parameters. We hypothesized that decreased 
serum CT-1 levels may predict improvement in metabolic outcomes after a WL 
program in overweight/obese children, since it has been suggested that the high levels 
of CT-1 in obese subjects could be a protective mechanism to counteract the emergence 
of obesity-related alterations [13]. 
2. SUBJECTS AND METHODS 
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2.1. Subjects 
In the study, 71 children between 7 and 15 yr and classified as overweight or obese 
according to the Cole et al. criteria [21] were invited to participate in the information 
session. Children were recruited from the Endocrinology Pediatric Units of the 
University of Navarra Clinic and Navarra’s Hospital Complex in Pamplona, Navarra. 
All of them were Spanish or schooling foreigners for at least one year in Spain. 
Participants with a major psychiatric illness, significant neurological disease, bulimia 
nervosa, familial hyperlipidemia or any sort of either major cardiovascular or 
respiratory complication, were excluded. Children and their parents signed a written 
informed consent. The study protocol was performed in accordance with the ethical 
standards of the Declaration of Helsinki, and was approved by the Ethics Committee of 
the University of Navarra (Reference Number 038/2009). From the initial 71 volunteers, 
54 successfully underwent baseline anthropometric measurements.  
Forty-four participants (22 boys, 22 girls) concluded the 10-week dietary intervention 
(drop-out rate 18.5%) during two different periods (from April to June and from 
September to December, 2010) and were assessed for WL after the moderate calorie 
restriction treatment. BMI-SDS was calculated as a function of the subject’s obesity 
degree when compared with BMI local reference standards [22], which is adjusted for 
sex and age and it is optimal for assessing adiposity in children. The response of 
participants to the WL program was based on changes in BMI-SDS. Subjects were 
dichotomized at the median of BMI-SDS (equal to 0.5). Those who lost >0.50 BMI-
SDS were considered as “High Responders” (HR; n=22) and those who lost ≤0.50 BMI-
SDS as “Low Responders” (LR; n=22) to the program. Previous studies have shown 
that an improvement in body composition and cardiometabolic risk can be seen with a 
BMI-SDS reduction of ≥0.25 in obese adolescents, while greater benefits accrue from 
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losing at least 0.5 BMI-SDS [6]. Baseline clinical and anthropometric characteristics of 
HR and LR are shown in table 1. 
2.2. Dietary treatment  
The child accompanied by his/her parent or tutor, received weekly individual sessions 
with a registered dietician for dietary follow-up, weight-control and nutritional 
education. The adherence to the ten weekly appointments with the registered dietician 
was 93% in the total sample. The study protocol consisted of a moderate calorie-
restricted diet, calculated according to children’s obesity degree [23], which did not 
interfere with the children’s body growth.  
Therefore, subjects were prescribed a diet based on a fixed full-day meal plan, 
calculated according to basal metabolic rate. Energy Expenditure was estimated taking 
into account basal metabolism using the Schofield equation, according to sex [24] and 
body growth period [25]. In all cases, diets were not lower than 1300 kcal and not 
higher than 2200 kcal. Children and their parents received personal training in 
nutritional and physical education throughout the intervention period. Identical personal 
physical training was also achieved.  
2.3. Anthropometric, clinical and biochemical measurements 
 All anthropometric and biochemical measures were carried out at baseline and after the 
10-week intervention, following validated procedures. Measurements were performed 
by trained personnel, in a wide space and all participants were barefoot and wore light 
clothing. All measurements were assessed three times and the final values were the 
mean from the data obtained. Body fat mass was estimated by bioelectrical impedance 
analysis (TBF-410, TANITA, Tokyo, Japan). Pubertal status was determined using the 
Tanner stage. Venous blood samples were obtained by specialized trained nurses at the 
Hospital after an overnight fast. Glucose, insulin and lipid profiles were determined by 
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standard autoanalyzer techniques. Insulin resistance was calculated from the 
homeostasis model assessment of insulin resistance (HOMA-IR) and another index, 
HOMA-AD, dividing HOMA-IR by adiponectin [26]. Additionally, the lipid 
accumulation product (LAP) was calculated, which is based on a combination of waist 
circumference (WC) and fasting triglycerides, and serves as a simple index for lipid 
over-accumulation among adults [27]. Since there is no data for the pediatric 
population, we calculated this index for children according to normal values of 
triglycerides and WC by age and sex. ELISA was used to measure high sensitivity IL-6, 
leptin, adiponectin and CNTF, all from R&D Systems, Minneapolis, MN. Serum CT-1 
concentration was determined by ELISA (sensitivity 20 pg/mL; inter- and intra-assay 
coefficient of variation 8.40%-3.36%) as previously described with minor modifications 
[13]. Briefly, serum samples were added in triplicates to 96-well plates precoated with 
rat polyclonal anti-mouse CT-1 antibody (R&D Systems) and blocked in 0.1% 
Casein/PBS. Then a sandwich complex was formed with a polyclonal CT-1 antibody, 
developed in our laboratory in New Zealand White rabbits [28] labeled with biotin. 
After incubation, the unbound material was washed off, and the streptavidin-peroxidase 
complex (Pierce, Illinois) was added for detection of the bound CT-1. Subsequently, 
plates were washed, and antibody binding was determined using 3,3,5,5- 
tetramethylbenzidine substrate. Absorbance was read at 450 nm and the concentration 
was determined by comparison with serial dilutions of recombinant human CT-1. 
2.4.  Definition and components of the metabolic syndrome  
We defined the MetS following the International Diabetes Federation definition (IDF) 
[29] for children aged 6-16 yr. According to this definition, the diagnosis of the MetS in 
children needs the presence of three risk factor components: WC above the 90th 
percentile, plus any 2 of the following factors: either systolic or diastolic blood pressure 
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≥130 mmHg or ≥85 mmHg respectively, or treatment with antihypertensive medication, 
triglyceride levels ≥150 mg/dL, HDL-cholesterol levels <40 mg/dL, and fasting plasma 
glucose levels ≥100 mg/dL or treatment for diabetes. At baseline and after the 
intervention the MetS criteria were applied to participants and the change in MetS 
components following the intervention was estimated. 
2.5.  Statistical analysis 
Statistical analyses were performed using SPSS for Windows 15.0 software (SPSS Inc., 
Chicago, IL). P < 0.05 was considered statistically significant. The Shapiro-Wilk test 
was used to determine variable distributions. The sample size calculation indicated that 
we needed 20 subjects. This estimation was based on the following assumptions: an 
alpha error of 5%, a power of 90%, and a mean difference of 42±9 units in serum CT-1 
levels after the intervention. 
To assess the differences of parametric values before treatment between groups, the 
unpaired t-test was performed. We contrasted before vs. after intervention in subjects 
distributed by response, using the paired t-test. In addition, partial correlation 
coefficients adjusted for Tanner stage were performed to analyze the association 
between the change in CT-1 levels and changes in others variables, such as total 
cholesterol and WC. We also fitted multivariable linear regression analyses to estimate 
different associations of serum CT-1 levels with anthropometric and metabolic 
parameters, adjusting for potential confounders (Tanner stage and baseline CT-1) and 
obtaining β coefficients and p-values. Finally, an analysis of covariance (ANCOVA) 
was performed to assess changes in CT-1 levels according to the change in the number 
of MetS components after the 10-week intervention program, adjusting for Tanner stage 
and baseline CT-1. 
3. RESULTS 
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At baseline, 91% of children who completed the 10-week WL program (22 boys and 22 
girls, mean age 11.5 yr) were obese and one third was at risk of developing MetS. 
Characteristics of overweight/obese children according to the intervention response (the 
HR group who lost >0.50 BMI-SDS and the LR group when they lost ≤0.50 BMI-SDS 
of their initial BMI-SDS) are shown in Table 1. No differences were found between the 
two groups at baseline.  
Both groups (HR and LR) after the intervention did significantly (p<0.05) decrease 
BMI-SDS, body fat, WC and serum glucose levels. After the 10-week intervention 
program, anthropometric and biochemical measurements significantly diminished in the 
HR group (Table 1). Mean WL was 3.73±0.24 kg, which corresponds to a 5.5% of the 
initial body weight (p<0.001) in the HR group. Specifically, they showed a significant 
reduction in BMI (-2 kg/m2, p<0.001), BMI-SDS (-0.78, p<0.001), body fat mass (-8%, 
p<0.001), WC (-5.4 cm, p<0.001) and heart rate (-7.6 bpm, p=0.028) after the WL 
program. The rapid losses of weight and body fat during the intervention were 
associated with a marked improvement in glucose and lipid metabolism. Serum glucose 
(-6 mg/dL, p<0.001), total cholesterol (-0.54 mmol/L, p<0.001), LDL-cholesterol (-0.34 
mmol/L, p=0.003), LAP (-9.84, p=0.009), insulin levels (-4.53 μU/mL, p=0.010) and 
HOMA-IR (-1.23, p=0.003) were significantly diminished. Notably, there was a 
decrease in serum CT-1 (-48 fmol/mL, p=0.043) levels in the HR group, while 
adiponectin levels were increased in these subjects (+1.03 μg/mL, p=0.012). No 
changes were observed in leptin, CNTF or IL-6 serum levels after the WL program in 
our population of overweight/obese children (Table 1). 
Positive correlations were found between the relative (%) change in serum CT-1 levels 
and the change in WC (r=0.432, p=0.050) or total cholesterol levels (r=0.611, p=0.003) 
after adjusting for Tanner stage, but only in the HR group (Figure 1). No significant 
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correlations were observed in the LR group (data not shown). Moreover, in a 
multivariable linear regression, the relative (%) change in CT-1 serum levels 
significantly predicted the 41% and 28% of the variance in changes in total cholesterol 
and LDL-cholesterol, respectively, in the HR group independently of Tanner stage and 
baseline CT-1, while no associations were found in the LR group (Table 2). 
The prevalence of MetS following the IDF criteria (as explained in the Subjects and 
Methods section) in the complete sample of overweight/obese children was 20% after 
the intervention (data not shown). When calculating the change in the MetS criteria 
after the WL program, we found subjects who decreased, maintained or either increased 
the number of MetS components, as shown in Figure 2. Interestingly, the lower the 
MetS risk factors, the lower the CT-1 levels after the 10-week nutritional intervention, 
(p ANCOVA=0.040, p trend=0.024). 
4. DISCUSSION  
This trial showed, for the first time, a decrease in serum CT-1 levels after a WL 
program in overweight/obese children and notably, that these diminished levels were 
strongly associated with a lower risk of developing the MetS. 
The increased obesity prevalence in children is causing a severe problem in childhood 
and later in life, because obesity is associated with many comorbidities such as 
hypertension, dyslipidemia and disturbed glucose metabolism [30,31]. According to 
evidence, what seems to be the most successful approach against obesity is intensive 
lifestyle modification that includes guidance on dietary aspects, food-related factors, 
physical activity, and behavioral strategies [32-34]. Moreover, family support is of 
utmost importance. In this sense, in our study these comorbidities were improved after a 
10-week nutritional intervention program that involved a modification of lifestyle 
habits. 
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Interestingly, overweight/obese children (HR and LR) had significantly reduced their 
BMI, BMI-SDS, body fat, WC and serum glucose levels after the intervention. 
Although, the LR group only maintained their body weight and showed no change in 
other parameters (such as CT-1). It is worthy to mention that overweight/obese children 
in our study were advised to follow a diet with a moderate calorie-restriction, so as not 
to interfere with their body growth. With regards to this, from a pediatrician’s 
perspective, it is favorable to have no increase in body weight, especially fat mass, 
during a nutritional intervention to treat obese children [35]. 
In a recent meta-analysis of 899 obese children, a significant pooled BMI reduction of 
1.25 kg/m2 [5] was reported, similar to the BMI change achieved in our 
overweight/obese children (2.0 kg/m2). A comparable observation was obtained for the 
percentage of body fat change in the former meta-analysis, with the lifestyle 
intervention group losing more than 3.2% of body fat than the usual care group [5]. 
Meanwhile, our overweight/obese children did show a higher reduction in body fat mass 
(-8%) after the WL program. 
Nevertheless, it is reported that body weight reductions (between 0.25-0.50 BMI-SDS) 
can trigger an improvement in metabolic outcomes in obese children [6,35-37]. In 
addition, it is seen that the degree of WL was associated with an improvement in the 
prevalence of MetS and its components [38], as confirmed by our study. 
Participants from the HR group showed increased adiponectin levels as expected [10]. 
Fasting glucose, insulin and insulin resistance (reduced HOMA-AD ratio and HOMA-
IR) were successfully reduced after the nutritional intervention, as reported elsewhere 
[11,12,39]. Similar to our work, important decreases in heart rate, total cholesterol, 
LDL-cholesterol and triglycerides were achieved after short term interventions in obese 
children [11,12,40,41].  
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However, we found no change in blood pressure, CNTF, leptin, and IL-6 serum levels 
in the HR group. CNTF is a pluripotent neurocytokine that mimics the biological 
actions of leptin overcoming "leptin resistance" [42], but no information on CNTF 
levels after a WL program is available. In our overweight/obese children circulating 
leptin did not change after the intervention, as shown by Cambuli et al. [10] in similar 
aged obese children. Moreover, it is reported that leptin concentration exhibits 
significant changes during progressive pubertal stages [43]. 
Furthermore, decreased levels or no change - as seen in our study for IL-6- were 
observed in obese children following WL programs [44-46]. The reported differences 
could be explained by the intervention design (duration, type, and lifestyle changes), 
characteristics of participants (age, sex, family lifestyle) and other factors. 
Strengths of our study include: 1) measurements in young subjects not confounded by 
chronic obesity-related disorders; 2) the overweight/obese subjects, especially HR, 
achieved substantial WL in a short term dietary intervention showing a good response to 
the diet (WL higher than 5% of initial body weight) [47,48] and 3) a standardized 
intervention with similar dietary conditions applied to a relatively homogeneous group. 
On the other hand, weaknesses of the study are: 1) the lack of the comparison group of 
normal-weight children; 2) the small number of children per group; and 3) a large 
number of participants were in progressive pubertal stages with a high rate of growth 
and significant endocrine changes. 
Interestingly, our study showed for the first time a significant decreased in CT-1 levels 
after a WL program in the HR overweight/obese children. Our results are in line with 
those reported for other cytokines such as leptin, IL-6 [44], or visfatin [49] in WL 
intervention studies with obese children from similar age ranges. Although, CT-1 is a 
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protective cytokine, Moreno-Aliaga et al. suggested that it could be increased in obesity 
as a compensatory mechanism to fight against this disease [13].  
Nevertheless, the change in CT-1 levels strongly predicted the 41% and 28% of the 
variance in changes in total cholesterol and LDL-cholesterol, respectively, during rapid 
WL in our overweight/obese children. Likely, Murer et al. [50] did show that changes in 
leptin levels were predictors for cholesterol and LDL-cholesterol after a WL program in 
obese children and adolescents [50]. Our results indicate that the greater the reduction in 
CT-1 levels, the greater the reduction in cholesterol levels, confirming the potential role 
of CT-1 in ameliorating unfavorable metabolic features. 
Moreover, we were able to show for the first time a relationship between CT-1 levels 
and MetS risk factors in overweight/obese children. Specifically, we found that the 
lower the CT-1 levels after the intervention, the higher the reduction in the risk of 
developing MetS. 
5. CONCLUSION 
Our study showed for the first time a decrease in serum CT-1 levels after a WL 
program, and these diminished CT-1 levels were strongly associated with a reduction in 
cholesterol levels and in the risk of developing MetS in overweight/obese children. 
Consequently, our data may suggest that CT-1 could be an indirect marker for the 
diagnosis of MetS in this population. 
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Table 1: Characteristics of overweight/obese children before and after 10-week of treatment according to the response. 1	
  High responders (n=22) Low responders (n=22)   
  Baseline 
After 
intervention p value1 Baseline 
After 
intervention p value1 p value2 
Sex (boys/girls, n) 14/8     8/14     0.073 
Tanner stage (I/II/III, n) 7/12/3     4/16/2     0.618 
Age (y) 11.23 ± 0.59     11.82 ± 0.52     0.458 
Weight (Kg) 68.16 ± 3.66 64.43 ± 3.58 <0.001 77.1 ± 4.87 76.46 ± 4.97 0.074 0.149 
Height (m) 1.51 ± 0.03 1.52 ± 0.03 <0.001 1.56 ± 0.03 1.56 ± 0.03 0.001 0.252 
Body fat (%) 35.59 ± 1.77 32.64 ± 1.55 <0.001 39.00 ± 1.58 38.21 ± 1.52 0.024 0.157 
BMI (kg/m2) 29.33 ± 0.85 27.33 ± 0.86 <0.001 31.18 ± 1.22 30.60 ± 1.26 0.001 0.221 
BMI-SDS 4.01 ± 0.39 3.23 ± 0.36 <0.001 3.99 ± 0.49 3.79 ± 0.50 <0.001 0.975 
Waist circumference (cm) 89.89 ± 2.11 84.49 ± 2.00 <0.001 92.34 ± 1.96 90.06 ± 2.14 0.006 0.400 
Hip circumference (cm) 98.50 ± 2.23 95.23 ± 2.22 <0.001 104.58 ± 2.93 103.72 ± 3.21 0.205 0.106 
		 23
Waist to hip ratio 0.91 ± 0.01 0.89 ± 0.01 <0.001 0.89 ± 0.01 0.87 ± 0.01 0.054 0.175 
Waist to height ratio 0.59 ± 0.01 0.56 ± 0.01 <0.001 0.59 ± 0.01 0.58 ± 0.01 0.002 0.967 
Systolic BP (mmHg) 127.95 ± 4.39 125.80 ± 3.28 0.695 131.05 ± 3.39 125.67 ± 3.40 0.211 0.578 
Diastolic BP (mmHg) 75.40 ± 3.25 70.10 ± 2.44 0.259 71.62 ± 3.94 67.67 ± 1.93 0.281 0.466 
Heart rate (bpm) 83.63 ± 2.85 76.05 ± 2.39 0.028 80.42 ± 2.55 78.58 ± 4.47 0.549 0.547 
Glucose (mg/dL) 93.00 ± 1.74 87.00 ± 1.71 <0.001 91.50 ± 1.04 85.68 ± 1.62 0.003 0.464 
Insulin (μU/mL) 17.92 ± 1.63 13.39 ± 1.36 0.010 17.95 ± 2.13 18.57 ± 2.73 0.649 0.992 
HOMA-IR 4.13 ± 0.38 2.90 ± 0.31 0.003 4.07 ± 0.49 3.99 ± 0.60 0.822 0.929 
HOMA-AD ratio 344.63 ± 91.07 223.66 ± 77.69 <0.001 339.16 ± 54.09 353.76 ± 66.47 0.604 0.453 
Total cholesterol (mmol/L) 4.61 ± 0.20 4.07 ± 0.18 <0.001 4.34 ± 0.15 4.33 ± 0.19 0.898 0.299 
HDL cholesterol (mmol/L) 1.33 ± 0.07 1.21 ± 0.06 0.001 1.23 ± 0.06 1.16 ± 0.05 0.005 0.415 
LDL cholesterol (mmol/L) 2.73 ± 0.16 2.39 ± 0.14 0.003 2.51 ± 0.12 2.54 ± 0.16 0.798 0.329 
Triglycerides (mmol/L) 0.99 ± 0.09 0.80 ± 0.08 0.050 1.23 ± 0.16 1.24 ± 0.18 0.991 0.184 
Lipid Accumulation Product (LAP) 33.98 ± 3.53 24.14 ± 3.91 0.009 44.98 ± 5.94 44.52 ± 8.34 0.938 0.120 
Ratio total cholesterol/HDL cholesterol 3.64 ± 0.21 3.55 ± 0.22 0.457 3.70 ± 0.23 3.85 ± 0.20 0.159 0.883 
		 24
Leptin (ng/mL) 26.95 ± 3.26 46.62 ± 6.86 0.050 36.62 ± 4.47 34.76 ± 4.84 0.693 0.095 
CNTF (pg/mL) 24.98 ± 0.19 24.94 ± 0.17 0.823 25.01 ± 0.17 25.09 ± 0.16 0.598 0.919 
Adiponectin (μg/mL) 7.62 ± 0.90 8.65 ± 1.04 0.012 6.03 ± 0.48 5.51 ± 0.36 0.130 0.101 
IL-6 (pg/mL) 2.13 ± 0.22 1.88 ± 0.26 0.404 1.84 ± 0.20 2.36 ± 0.37 0.072 0.327 
CT-1 (fmol/mL) 653.58 ± 89.05 605.58 ± 83.50 0.043 461.38 ± 78.23 452.85 ± 62.53 0.837 0.114 
Variables are expressed as mean ± SEM. BMI-SDS: Standard Deviation Score for BMI; BP: Blood Pressure; HOMA-IR: Homeostasis Model 
Assessment of Insulin Resistance; HOMA-AD: HOMA to adiponectin ratio; CNTF: Ciliary Neurotrophic Factor; IL-6: Interleukin-6; CT-1: 
Cardiotrophin-1.          
1: p value for the comparison between before and after intervention in subjects distributed by the response.       
2: p value for the comparison at baseline between high and low responders.  
              
 2	
3	
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Table 2: Association between the percentage of change of CT-1, after the 10-week intervention, with changes in anthropometric and metabolic 5	
measures in the high and low responder groups of overweight/obese children: multivariable linear regression analyses. 6	
CT-1: Cardiotrophin-1; WC: Waist Circumference; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance. 7	
1 Crude standardized regression value, n=22. 8	
2 Adjusted for Tanner stage and baseline CT-1.9	
 
      
% Δ                  
LDL cholesterol     
% Δ                 
HOMA-IR 
 
  
% Δ               
WC     
% Δ                   
Total Cholesterol   
 
  β  p     β  p   β  p     β  p 
High responders 
(n=22) 
% Δ CT-11 0.430 0.046     0.619 0.002   0.520 0.016      -0.239 0.285 
% Δ CT-12 0.428 0.057     0.648 0.003   0.532 0.023      -0.280 0.265 
Low responders 
(n=22) 
% Δ CT-11 0.265 0.246   0.078 0.738  0.149 0.520   -0.149 0.520 
% Δ CT-12 0.293 0.201   0.074 0.753  0.171 0.458   -0.120 0.606 
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Figure 1: Association between the change in CT-1 levels (%) and in waist circumference or total cholesterol levels after the intervention. 11	
Positive correlations were found in the HR group (A,B), after adjusting for Tanner stage.12	
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Figure 2: The change in serum CT-1 levels (%) after the 10-week intervention, according to the change in MetS risk components. Between 16	
group comparison for the three groups: p (ANCOVA) = 0.040 after adjusting for Tanner stage and baseline CT-1. *: p<0.05 between participants 17	
who decreased or maintained vs. increased MetS risk components. 18	
